AS601245

• Description:

  AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  JNK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/AS601245.html

• Concentration:

  10mM

• Purity:

  98.19

• Solubility:

  DMSO : 10 mg/mL (ultrasonic)

• Smiles:

  N#CC(C1=CC=NC(NCCC2=CC=CN=C2)=N1)C3=NC4=CC=CC=C4S3

• Molecular Formula:

  C20H16N6S

• Molecular Weight:

  372.45

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Carboni S, et al. AS601245 (1,3-benzothiazol-2-yl (2-[[2- (3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile) : a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004;310 (1) :25-32.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  JNK1; JNK2; JNK3

• CAS Number:

  345987-15-7